These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31053780)

  • 1. A novel de novo MTOR gain-of-function variant in a patient with Smith-Kingsmore syndrome and Antiphospholipid syndrome.
    Rodríguez-García ME; Cotrina-Vinagre FJ; Bellusci M; Martínez de Aragón A; Hernández-Sánchez L; Carnicero-Rodríguez P; Martín-Hernández E; Martínez-Azorín F
    Eur J Hum Genet; 2019 Sep; 27(9):1369-1378. PubMed ID: 31053780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smith-Kingsmore syndrome: A third family with the MTOR mutation c.5395G>A p.(Glu1799Lys) and evidence for paternal gonadal mosaicism.
    Moosa S; Böhrer-Rabel H; Altmüller J; Beleggia F; Nürnberg P; Li Y; Yigit G; Wollnik B
    Am J Med Genet A; 2017 Jan; 173(1):264-267. PubMed ID: 27753196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and structural analyses of novel Smith-Kingsmore Syndrome-Associated MTOR variants reveal potential new mechanisms and predictors of pathogenicity.
    Besterman AD; Althoff T; Elfferich P; Gutierrez-Mejia I; Sadik J; Bernstein JA; van Ierland Y; Kattentidt-Mouravieva AA; Nellist M; Abramson J; Martinez-Agosto JA
    PLoS Genet; 2021 Jul; 17(7):e1009651. PubMed ID: 34197453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delineating the Smith-Kingsmore syndrome phenotype: Investigation of 16 patients with the MTOR c.5395G > A p.(Glu1799Lys) missense variant.
    Poole RL; Curry PDK; Marcinkute R; Brewer C; Coman D; Hobson E; Johnson D; Lynch SA; Saggar A; Searle C; Scurr I; Turnpenny PD; Vasudevan P; Tatton-Brown K
    Am J Med Genet A; 2021 Aug; 185(8):2445-2454. PubMed ID: 34032352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new case of Smith-Kingsmore syndrome with somatic MTOR pathogenic variant expands the phenotypic spectrum to lateralized overgrowth.
    Carli D; Ferrero GB; Fusillo A; Coppo P; La Selva R; Zinali F; Cardaropoli S; Ranieri C; Iacoviello M; Resta N; Mussa A
    Clin Genet; 2021 May; 99(5):719-723. PubMed ID: 33506498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Smith-Kingsmore syndrome caused by MTOR gene variation: 2 cases and literature review].
    Lei HH; Liu LL; Wang XL; Tie XC; Tian N; Ji Y; Yang Y
    Zhonghua Er Ke Za Zhi; 2022 Sep; 60(9):935-939. PubMed ID: 36038305
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and functional studies of MTOR variants in Smith-Kingsmore syndrome reveal deficits of circadian rhythm and sleep-wake behavior.
    Liu AC; Shen Y; Serbinski CR; He H; Roman D; Endale M; Aschbacher-Smith L; King KA; Granadillo JL; López I; Krueger DA; Dye TJ; Smith DF; Hogenesch JB; Prada CE
    HGG Adv; 2024 Oct; 5(4):100333. PubMed ID: 39030910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR mutations in Smith-Kingsmore syndrome: Four additional patients and a review.
    Gordo G; Tenorio J; Arias P; Santos-Simarro F; García-Miñaur S; Moreno JC; Nevado J; Vallespin E; Rodriguez-Laguna L; de Mena R; Dapia I; Palomares-Bralo M; Del Pozo Á; Ibañez K; Silla JC; Barroso E; Ruiz-Pérez VL; Martinez-Glez V; Lapunzina P
    Clin Genet; 2018 Apr; 93(4):762-775. PubMed ID: 28892148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent mosaic MTOR c.5930C > T (p.Thr1977Ile) variant causing megalencephaly, asymmetric polymicrogyria, and cutaneous pigmentary mosaicism: Case report and review of the literature.
    Handoko M; Emrick LT; Rosenfeld JA; Wang X; Tran AA; Turner A; Belmont JW; ; Lee BH; Bacino CA; Chao HT
    Am J Med Genet A; 2019 Mar; 179(3):475-479. PubMed ID: 30569621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Missense Variant in the Gene
    Yan L; Shen R; Cao Z; Han C; Zhang Y; Liu Y; Yang X; Xie M; Li H
    Biomed Res Int; 2021; 2021():6661860. PubMed ID: 33628804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalities.
    Mroske C; Rasmussen K; Shinde DN; Huether R; Powis Z; Lu HM; Baxter RM; McPherson E; Tang S
    BMC Med Genet; 2015 Nov; 16():102. PubMed ID: 26542245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain-of-function variants in the ODC1 gene cause a syndromic neurodevelopmental disorder associated with macrocephaly, alopecia, dysmorphic features, and neuroimaging abnormalities.
    Rodan LH; Anyane-Yeboa K; Chong K; Klein Wassink-Ruiter JS; Wilson A; Smith L; Kothare SV; Rajabi F; Blaser S; Ni M; DeBerardinis RJ; Poduri A; Berry GT
    Am J Med Genet A; 2018 Dec; 176(12):2554-2560. PubMed ID: 30475435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the phenotype of PURA-related neurodevelopmental disorder: a close differential diagnosis of infantile hypotonia with psychomotor retardation and characteristic facies.
    Mishra S; Girisha KM; Shukla A
    Clin Dysmorphol; 2021 Jan; 30(1):1-5. PubMed ID: 33229923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide as a potential treatment for obesity in Smith-Kingsmore syndrome (SKS) patients: A mosaic mutation case report.
    Bonnet JB; Durieux AT; Tournayre S; Marty L; Sultan A; Avignon A
    Obes Res Clin Pract; 2024; 18(2):159-162. PubMed ID: 38582735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo loss-of-function KCNMA1 variants are associated with a new multiple malformation syndrome and a broad spectrum of developmental and neurological phenotypes.
    Liang L; Li X; Moutton S; Schrier Vergano SA; Cogné B; Saint-Martin A; Hurst ACE; Hu Y; Bodamer O; Thevenon J; Hung CY; Isidor B; Gerard B; Rega A; Nambot S; Lehalle D; Duffourd Y; Thauvin-Robinet C; Faivre L; Bézieau S; Dure LS; Helbling DC; Bick D; Xu C; Chen Q; Mancini GMS; Vitobello A; Wang QK
    Hum Mol Genet; 2019 Sep; 28(17):2937-2951. PubMed ID: 31152168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial involvement in a Bosch-Boonstra-Schaaf optic atrophy syndrome patient with a novel de novo NR2F1 gene mutation.
    Martín-Hernández E; Rodríguez-García ME; Chen CA; Cotrina-Vinagre FJ; Carnicero-Rodríguez P; Bellusci M; Schaaf CP; Martínez-Azorín F
    J Hum Genet; 2018 Apr; 63(4):525-528. PubMed ID: 29410510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain Tissue Low-Level Mosaicism for
    Szczałuba K; Rydzanicz M; Walczak A; Kosińska J; Koppolu A; Biernacka A; Iwanicka-Pronicka K; Grajkowska W; Jurkiewicz E; Kowalczyk P; Płoski R
    Diagnostics (Basel); 2021 Jul; 11(7):. PubMed ID: 34359351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotype and phenotype correlations for SHANK3 de novo mutations in neurodevelopmental disorders.
    Li Y; Jia X; Wu H; Xun G; Ou J; Zhang Q; Li H; Bai T; Hu Z; Zou X; Xia K; Guo H
    Am J Med Genet A; 2018 Dec; 176(12):2668-2676. PubMed ID: 30537371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gain-of-function MARK4 variant associates with pediatric neurodevelopmental disorder and dysmorphism.
    Samra S; Sharma M; Vaseghi-Shanjani M; Del Bel KL; Byres L; Lin S; Dalmann J; Salman A; Mwenifumbo J; Modi BP; Biggs CM; Boelman C; Clarke LA; Lehman A; Turvey SE
    HGG Adv; 2024 Jan; 5(1):100259. PubMed ID: 38041405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable Clinical Manifestations of Xia-Gibbs syndrome: Findings of Consecutively Identified Cases at a Single Children's Hospital.
    Ritter AL; McDougall C; Skraban C; Medne L; Bedoukian EC; Asher SB; Balciuniene J; Campbell CD; Baker SW; Denenberg EH; Mazzola S; Fiordaliso SK; Krantz ID; Kaplan P; Ierardi-Curto L; Santani AB; Zackai EH; Izumi K
    Am J Med Genet A; 2018 Sep; 176(9):1890-1896. PubMed ID: 30152016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.